SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.047
EU - Europa 2.806
AS - Asia 1.332
SA - Sud America 45
AF - Africa 12
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.255
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.019
IT - Italia 1.274
PL - Polonia 717
SG - Singapore 523
CN - Cina 502
DE - Germania 243
GB - Regno Unito 126
ID - Indonesia 117
FI - Finlandia 99
UA - Ucraina 95
SE - Svezia 87
VN - Vietnam 70
TR - Turchia 67
BR - Brasile 37
FR - Francia 37
NL - Olanda 26
BE - Belgio 25
CA - Canada 25
AT - Austria 21
LT - Lituania 18
IN - India 15
CM - Camerun 9
HK - Hong Kong 8
KR - Corea 8
CZ - Repubblica Ceca 7
IE - Irlanda 7
AU - Australia 6
CH - Svizzera 6
RU - Federazione Russa 6
EU - Europa 5
IR - Iran 3
MY - Malesia 3
PE - Perù 3
ZA - Sudafrica 3
AL - Albania 2
BG - Bulgaria 2
CL - Cile 2
LK - Sri Lanka 2
NO - Norvegia 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
BO - Bolivia 1
CO - Colombia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
ES - Italia 1
GE - Georgia 1
IL - Israele 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
JP - Giappone 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MX - Messico 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SM - San Marino 1
TW - Taiwan 1
Totale 9.255
Salva come PNG Salva come JPEG
Città #
Warsaw 715
Fairfield 588
Santa Clara 552
Ashburn 548
Singapore 406
Chandler 348
Woodbridge 309
Beijing 248
Houston 237
Wilmington 236
Seattle 218
Cambridge 176
Princeton 154
Ferrara 128
Jakarta 113
Ann Arbor 111
Jacksonville 102
Milan 90
Helsinki 76
Munich 70
Dong Ket 69
San Diego 68
Shanghai 68
Bremen 59
Rome 50
Izmir 47
Bologna 45
Los Angeles 44
London 43
Washington 42
Boardman 38
Falls Church 37
Nanjing 37
Redwood City 31
Dearborn 27
Addison 26
Brussels 23
Nuremberg 23
Falkenstein 22
Santa Maria Di Sala 22
New York 19
Verona 16
Mountain View 15
Norwalk 15
San Mateo 15
Frankfurt am Main 14
Padova 14
Toronto 12
Shenyang 10
Tianjin 10
Nanchang 9
Vienna 9
Louisville 8
Ottawa 8
Augusta 7
Ferrara di Monte Baldo 7
Florence 7
Hong Kong 7
Jiaxing 7
Lappeenranta 7
Palermo 7
Chicago 6
Hebei 6
Jinan 6
Naples 6
Turin 6
Zhengzhou 6
Andover 5
Auburn Hills 5
Castelnuovo Rangone 5
Chiswick 5
Cordenons 5
Feltre 5
Pisa 5
Taizhou 5
Arezzo 4
Birmingham 4
Dublin 4
Forlì 4
Genoa 4
Guangzhou 4
Hangzhou 4
Kunming 4
Messina 4
Paris 4
Parma 4
Rimini 4
São Paulo 4
Torino 4
Trento 4
Zonguldak 4
Ancona 3
Belo Horizonte 3
Brescia 3
Brno 3
Cagliari 3
Cascina 3
Catania 3
Chilly-mazarin 3
Des Moines 3
Totale 6.636
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 569
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 266
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 198
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 142
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 123
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 118
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 114
Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors 112
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 112
null 106
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 103
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 100
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 99
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 98
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 94
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 94
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 94
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 93
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 91
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 83
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 82
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 82
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 81
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 81
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 81
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 79
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 77
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 77
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 76
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 76
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 76
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 76
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 76
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 75
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 75
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 74
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 73
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 72
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 72
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 72
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 72
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 72
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 71
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 71
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 71
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 71
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 71
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 70
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 70
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 70
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 70
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 69
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 68
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 68
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 67
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 67
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 66
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 66
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 66
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 65
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 65
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 65
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 64
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 64
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 63
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 63
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 62
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 62
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 61
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 61
FOLLOW-UP SIEROLOGICO DI PAZIENTE AFFETTO DA RECIDIVA DI IDATIDOSI EPATICA ED INTOLLERANZA ALL’ALBENDAZOLO (ABZ). 59
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 57
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 57
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 57
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 56
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 56
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 56
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens 55
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 54
Associations between immune depression and cardiovascular events in HIV infection 54
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 54
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 54
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 53
null 53
RIACUTIZZAZIONE DI EPATITE CRONICA HBV-RELATA DOPO VACCINAZIONE ANTINFLUENZALE. DESCRIZIONE DI UN CASO CLINICO 51
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 51
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome 50
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 49
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 49
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 49
null 48
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 48
Time to undetectable viral load achievement after art start and risk of mortality. 47
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 47
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 46
null 46
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 46
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 46
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies 44
La applicazione delle Linee Guida Italiane di terapia antiretrovirale nella realtà ambulatoriale: efficacia e tollerabilità della cART di prima linea. 44
Totale 7.889
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.684
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.364
Totale 70.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.046 0 0 0 0 0 0 0 33 398 294 158 163
2020/20212.578 142 269 132 312 301 303 224 211 124 310 89 161
2021/20221.086 74 96 23 15 57 89 56 65 38 121 53 399
2022/2023988 158 65 66 54 173 92 52 95 117 12 71 33
2023/20241.102 55 100 82 41 115 223 27 74 34 29 37 285
2024/20251.905 101 88 350 163 469 482 155 97 0 0 0 0
Totale 9.626